Next Article in Journal
Comparison of Anti-Microbial Effects of Low-Level Laser Irradiation and Microwave Diathermy on Gram-Positive and Gram-Negative Bacteria in an In Vitro Model
Previous Article in Journal
Urotensin 2 and Oxidative Stress Levels in Maternal Serum in Pregnancies Complicated by Intrauterine Growth Restriction
Article Menu

Export Article

Open AccessArticle

The Influence of Cardiovascular Medications on Iron Metabolism in Patients with Heart Failure

1
Department of Internal Medicine, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
2
Independent Researcher, 700115 Iasi, Romania
3
Department of Pharmaceutical Chemistry, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
4
Department of Microbiology, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
5
Department of Pharmacology, Gr. T. Popa University of Medicine and Pharmacy, 700115 Iasi, Romania
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(7), 329; https://doi.org/10.3390/medicina55070329
Received: 12 May 2019 / Revised: 16 June 2019 / Accepted: 27 June 2019 / Published: 2 July 2019
  |  
PDF [455 KB, uploaded 2 July 2019]
  |  

Abstract

Background and objectives: The etiology of anemia associated with heart failure is not fully understood, but there are data suggesting the involvement of multiple mechanisms, including various drug therapies used in patients with heart failure. Our primary objective was to evaluate the impact of beta blockers, angiotensin-converting enzyme inhibitors, and calcium-channel blockers on iron metabolism in patients with heart failure. Materials and Methods: This was a prospective observational study that included patients diagnosed with heart failure and iron deficiency (defined by ferritin <100 μg/L, or 100–300 μg/L with transferrin saturation <20%). Patients with anemia secondary to a known cause were excluded. Results: We found a statistically significant correlation between beta-blocker treatment and ferritin values (p = 0.02). Iron, hemoglobin, and hematocrit levels were significantly lower in the patients using calcium-channel blockers than those who were not. We also found a statistically significant indirect correlation (p = 0.04) between the use of angiotensin-converting enzyme inhibitors and hematocrit levels. Conclusion: The contribution of our study arises from the additional data regarding the drug-induced etiology of iron deficiency. Practitioners should be aware of the potential impact of therapeutic recommendations and this should imply a close monitoring of the biochemical parameters of iron deficiency in this category of patients. View Full-Text
Keywords: iron deficiency; heart failure; beta blockers; calcium-channel blockers; angiotensin-converting enzyme inhibitors iron deficiency; heart failure; beta blockers; calcium-channel blockers; angiotensin-converting enzyme inhibitors
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Sirbu, O.; Sorodoc, V.; Jaba, I.M.; Floria, M.; Stoica, A.; Profire, L.; Tuchilus, C.; Rusu, G.; Sorodoc, L. The Influence of Cardiovascular Medications on Iron Metabolism in Patients with Heart Failure. Medicina 2019, 55, 329.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicina EISSN 1010-660X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top